Developer docs
API playgroundTry for free, no card

Search company profiles

Resoundant

Full company profile

uuid000qlrm

Namestring
Resoundant
Legal namestring
Resoundant, Inc.
Websiteurl
resoundant.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Resoundant, Inc. is a privately held medical technology company headquartered in Rochester, Minnesota that commercializes Magnetic Resonance Elastography (MRE), a non-invasive imaging technology invented at Mayo Clinic by CEO Richard Ehman and colleagues in the 1990s. MRE is an FDA-cleared software and hardware upgrade deployed on existing MRI systems; it converts MR phase data into quantitative, reproducible measurements of tissue stiffness (in kilopascals) using standardized computational algorithms that produce biomarkers of liver fibrosis consistent across operators, scanners, and field strengths. The product portfolio includes the core 2D MRE technology, the advanced 3D MRE and Hepatogram+ multiparametric package for clinical trials, the Flex Driver hardware system that generates shear waves, the MRI-PDFF companion technology for hepatic steatosis quantification, and the MRE:connect patient-facing directory of imaging centers.

The company operates a hybrid business model. It licenses its MRE technology to the three global MRI manufacturers (GE Healthcare, Siemens Healthineers, Philips Healthcare), who embed it as FDA-cleared functionality on their scanners; it manufactures and sells Flex Driver hardware; it operates MRE:connect, a consumer-facing directory of 1,300+ US imaging centers offering MRE; and it provides core lab, central image read, and regulatory support services to pharmaceutical and biotech sponsors running NAFLD, NASH, and MASH clinical trials. Resoundant serves four primary customer segments: hospital radiology departments and imaging centers, hepatology and gastroenterology practices, pharmaceutical and biotech companies conducting liver disease trials, and patients with chronic liver disease. The technology is FDA-cleared, reimbursed under CMS Category I CPT code 76391 at approximately $240 per exam, and recognized by the American College of Radiology as the most accurate non-invasive liver fibrosis exam. As of 2024, MRE is available at more than 2,500 imaging centers globally.

Short descriptiontext

Resoundant commercializes Magnetic Resonance Elastography (MRE), an FDA-cleared non-invasive MRI-based liver fibrosis assessment technology invented at Mayo Clinic, serving radiology providers, hepatology practices, pharmaceutical trial sponsors, and liver disease patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRochester, United States
HQ citystring
Rochester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
magnetic resonance elastography, liver fibrosis imaging, quantitative MRI biomarkers, noninvasive liver diagnostics, clinical trial core lab services
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging Software - Liver Fibrosis Diagnostics
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1MRE Driver Hardware Systems
TypeHardware Sales
Description

Resoundant designs and manufactures MRE driver systems (Flex Driver and active drivers) that generate low frequency mechanical waves transmitted to passive drivers placed on patients. These hardware systems are sold to MRI manufacturers and directly to imaging centers.

resoundant.com
2Technology Licensing to MRI Manufacturers
TypeLicensing Royalties
Description

Resoundant assists MRI manufacturers (GE, Siemens, Philips) in implementing MRE as FDA-cleared products. The company receives licensing royalties and ongoing revenue from these OEM partnerships.

resoundant.com
3Clinical Trial Services
TypeProfessional Services
Description

Resoundant provides central image reads, secure data management, quantitative reporting, site training and identification, regulatory support, study start-up/close-out support, quality control, and proprietary in-house analytics for pharmaceutical clinical trials. Revenue generated from consulting and core lab services for NAFLD/NASH trials.

resoundant.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Standalone MRE Exam - Medicare Reimbursement
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$240 per exam reimbursement level under CMS Category I CPT code (76391). Approximately $200 under Medicare for patients.

resoundant.com
2Combined MRE + PDFF Exam
ModelUnit PricingBilling cadencePay-as-you-go
Notes

MRE and MRI-PDFF can be paired and reimbursed under the same CPT code for a rapid, highly accurate, low-cost exam for liver fat and fibrosis assessment.

resoundant.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1MRE:connect
Description

Online directory of leading radiology and imaging centers offering MR Elastography for liver fibrosis staging.

resoundant.com
+1 more record
Core offering1 text field

Resoundant develops, manufactures, and licenses Magnetic Resonance Elastography (MRE) technology for non-invasive liver fibrosis assessment. The company provides MRE driver hardware systems and processing software to MRI manufacturers (GE Healthcare, Siemens, Philips) as FDA-cleared upgrades, and offers core lab clinical trial services directly to pharmaceutical companies for NAFLD/NASH drug development. Its proprietary technology converts MRI data into quantitative, reproducible biomarkers of liver stiffness.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • MRE diagnostic performance above 0.90 AUC for classifying all stages of liver fibrosis
+5 more records
Product overview1 text field

Resoundant offers a unified portfolio centered on Magnetic Resonance Elastography (MRE) technology for non-invasive liver disease diagnosis. The core product is FDA-cleared MRE, implemented as an upgrade across GE, Siemens, and Philips MRI systems. Key offerings include: MRE (core technology for liver stiffness measurement), Hepatogram+ (advanced multiparametric 3D MRE for clinical trials), Flex Driver (hardware component), PDFF imaging (companion fat quantification technology), MRE:connect (patient location service), and Clinical Trial Services (core lab and research support). The technology was invented at Mayo Clinic and enables quantitative, reproducible liver fibrosis assessment as an alternative to invasive biopsy.

Product and service5 records
1Magnetic Resonance Elastography (MRE)
CategoryMedical Imaging Software
Description

FDA-cleared quantitative imaging technology that converts MRI data into precise, reproducible measurements of tissue stiffness for liver fibrosis assessment. Deployed as an upgrade to existing MRI systems at thousands of sites worldwide for non-invasive liver disease diagnosis.

2Hepatogram+
3Flex Driver
4MRE:connect
CategoryPatient Service Platform
Description

Online directory of leading radiology and imaging centers offering MR Elastography for liver fibrosis staging, enabling patients to find and contact MRE-capable locations near them.

5Clinical Trial Services
CategoryClinical Trial Services
Description

Core lab services for clinical trials including central image reads, secure data management, quantitative reporting, site training and identification, regulatory support, study start-up/close-out support, quality control, and proprietary in-house analytics for MRE and PDFF biomarkers.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Contract Research Organizations (CROs)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-08-12
Description

Resoundant leverages connections with talented contract research organizations across the globe for clinical trial services, providing core lab and central image read services for NAFLD/NASH trials.

resoundant.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-05-21
Description

Resoundant joined the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) project - a €46.5m European research initiative funded by the European Innovative Medicines Initiative. The consortium includes 53+ academic centers and pharmaceutical companies working to develop non-invasive diagnostic tests for NAFLD. Resoundant provides advanced 3D MRE software and technological expertise. Budget supported by EU and contributing industry partners including Pfizer (lead EFPIA partner), AstraZeneca, Bristol-Myers Squibb, Allergan, Echosens, and HistoIndex.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

Resoundant partnered with Siemens to introduce MRE for their MRI systems, expanding global availability of the technology alongside GE and Philips implementations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

Resoundant partnered with Philips Healthcare to implement MRE for their MRI systems. Philips has collaborated with Resoundant on MRE research, including work with Dr. Daniel Podberesky on pediatric MRE applications.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2009-01-01
Description

GE Healthcare was the first MRI manufacturer to implement MRE as an FDA-cleared technology in 2009, making MRE available worldwide. Resoundant worked with GE to commercialize the technology as MR-Touch. GE continues as a key OEM partner implementing standardized MRE across their MRI systems.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2007-01-01
Description

Resoundant is a Mayo Clinic company founded by Mayo Foundation for Medical Education & Research, Mayo Clinic physicians and researchers. MRE was invented at Mayo Clinic and first implemented as a standard diagnostic test there in 2007. Mayo Clinic continues as key research and clinical development partner. Dr. Richard Ehman serves as both Mayo Clinic radiologist and Resoundant CEO.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Hologic is a women's-health and diagnostic imaging company with adjacent capability in clinical diagnostics and quantitative imaging biomarkers relevant to liver disease trial services.

TypeBroad incumbent
Description

Siemens Healthineers is an OEM licensee of MRE and a broad incumbent in MRI, with overlapping capability to develop proprietary elastography or substitute imaging modalities in the liver diagnostic space.

TypeOthers
Description

Canon Medical Systems is a major MRI manufacturer that competes in the scanner market where Resoundant's OEM partners compete, and could potentially license or develop elastography as an alternative to MRE.

TypeBroad incumbent
Description

GE Healthcare is both Resoundant's first OEM partner (MRE commercialized 2009) and a broader incumbent in MRI and diagnostic imaging that could develop or substitute competing elastography technologies.

TypeOthers
Description

Median Technologies provides imaging biomarkers and AI-based image analysis for oncology and liver clinical trials, offering central read and quantitative imaging services that overlap with Resoundant's clinical trial services franchise.

TypeDirect peer
Description

HistoIndex is a LITMUS consortium partner offering stain-free digital pathology for NASH/NAFLD assessment; it competes with MRE as an alternative non-invasive or minimally invasive biomarker approach in pharma trials and clinical research.

TypeBroad incumbent
Description

Philips Healthcare licenses MRE and is a broad incumbent in MRI and diagnostic imaging with the resources to develop or substitute liver elastography capabilities across its installed base.

TypeDirect peer
Description

Perspectum offers LiverMultiScan, an MRI-based multiparametric liver assessment that competes head-to-head with MRE for non-invasive liver fibrosis and steatosis quantification in clinical and trial settings.

9OWL (One Way Liver)
TypeEmerging player
Description

OWL develops blood-based lipidomics biomarkers for NAFLD/NASH diagnosis and is part of the LITMUS consortium; it represents an emerging non-imaging alternative to MRE for fibrosis and steatosis assessment.

10Echosens
TypeDirect peer
Description

Echosens manufactures FibroScan, the dominant ultrasound-based transient elastography device for liver fibrosis assessment, directly competing with MRE for first- and second-line liver fibrosis staging across hepatology practices.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resoundant

Medical Imaging Software - Liver Fibrosis Diagnosticsresoundant.com

Resoundant commercializes Magnetic Resonance Elastography (MRE), an FDA-cleared non-invasive MRI-based liver fibrosis assessment technology invented at Mayo Clinic, serving radiology providers, hepatology practices, pharmaceutical trial sponsors, and liver disease patients.

What Resoundant does

Resoundant, Inc. is a privately held medical technology company headquartered in Rochester, Minnesota that commercializes Magnetic Resonance Elastography (MRE), a non-invasive imaging technology invented at Mayo Clinic by CEO Richard Ehman and colleagues in the 1990s. MRE is an FDA-cleared software and hardware upgrade deployed on existing MRI systems; it converts MR phase data into quantitative, reproducible measurements of tissue stiffness (in kilopascals) using standardized computational algorithms that produce biomarkers of liver fibrosis consistent across operators, scanners, and field strengths. The product portfolio includes the core 2D MRE technology, the advanced 3D MRE and Hepatogram+ multiparametric package for clinical trials, the Flex Driver hardware system that generates shear waves, the MRI-PDFF companion technology for hepatic steatosis quantification, and the MRE:connect patient-facing directory of imaging centers.

The company operates a hybrid business model. It licenses its MRE technology to the three global MRI manufacturers (GE Healthcare, Siemens Healthineers, Philips Healthcare), who embed it as FDA-cleared functionality on their scanners; it manufactures and sells Flex Driver hardware; it operates MRE:connect, a consumer-facing directory of 1,300+ US imaging centers offering MRE; and it provides core lab, central image read, and regulatory support services to pharmaceutical and biotech sponsors running NAFLD, NASH, and MASH clinical trials. Resoundant serves four primary customer segments: hospital radiology departments and imaging centers, hepatology and gastroenterology practices, pharmaceutical and biotech companies conducting liver disease trials, and patients with chronic liver disease. The technology is FDA-cleared, reimbursed under CMS Category I CPT code 76391 at approximately $240 per exam, and recognized by the American College of Radiology as the most accurate non-invasive liver fibrosis exam. As of 2024, MRE is available at more than 2,500 imaging centers globally.

Resoundant firmographics

Firmographics
Name
Resoundant
Legal name
Resoundant, Inc.
Website
https://resoundant.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Resoundant commercializes Magnetic Resonance Elastography (MRE), an FDA-cleared non-invasive MRI-based liver fibrosis assessment technology invented at Mayo Clinic, serving radiology providers, hepatology practices, pharmaceutical trial sponsors, and liver disease patients.
Ownership category
akta.pro rank

Where Resoundant is headquartered

Location

Headquarters

HQ city
Rochester
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Resoundant business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. MRE Driver Hardware Systems: Resoundant designs and manufactures MRE driver systems (Flex Driver and active drivers) that generate low frequency mechanical waves transmitted to passive drivers placed on patients. These hardware systems are sold to MRI manufacturers and directly to imaging centers.
  2. Technology Licensing to MRI Manufacturers: Resoundant assists MRI manufacturers (GE, Siemens, Philips) in implementing MRE as FDA-cleared products. The company receives licensing royalties and ongoing revenue from these OEM partnerships.
  3. Clinical Trial Services: Resoundant provides central image reads, secure data management, quantitative reporting, site training and identification, regulatory support, study start-up/close-out support, quality control, and proprietary in-house analytics for pharmaceutical clinical trials. Revenue generated from consulting and core lab services for NAFLD/NASH trials.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandalone MRE Exam - Medicare Reimbursement
Unit PricingPay-as-you-goCombined MRE + PDFF Exam

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Resoundant product offering

Product offering

Core offering

Resoundant develops, manufactures, and licenses Magnetic Resonance Elastography (MRE) technology for non-invasive liver fibrosis assessment. The company provides MRE driver hardware systems and processing software to MRI manufacturers (GE Healthcare, Siemens, Philips) as FDA-cleared upgrades, and offers core lab clinical trial services directly to pharmaceutical companies for NAFLD/NASH drug development. Its proprietary technology converts MRI data into quantitative, reproducible biomarkers of liver stiffness.

Product overview

Resoundant offers a unified portfolio centered on Magnetic Resonance Elastography (MRE) technology for non-invasive liver disease diagnosis. The core product is FDA-cleared MRE, implemented as an upgrade across GE, Siemens, and Philips MRI systems. Key offerings include: MRE (core technology for liver stiffness measurement), Hepatogram+ (advanced multiparametric 3D MRE for clinical trials), Flex Driver (hardware component), PDFF imaging (companion fat quantification technology), MRE:connect (patient location service), and Clinical Trial Services (core lab and research support). The technology was invented at Mayo Clinic and enables quantitative, reproducible liver fibrosis assessment as an alternative to invasive biopsy.

Differentiator

Problem solved

Functional benefit

Brands

  • MRE:connect: Online directory of leading radiology and imaging centers offering MR Elastography for liver fibrosis staging.
  • Hepatogram+

Products and services

  • Magnetic Resonance Elastography (MRE) FDA-cleared quantitative imaging technology that converts MRI data into precise, reproducible measurements of tissue stiffness for liver fibrosis assessment. Deployed as an upgrade to existing MRI systems at thousands of sites worldwide for non-invasive liver disease diagnosis.
  • Hepatogram+
  • Flex Driver
  • MRE:connect Online directory of leading radiology and imaging centers offering MR Elastography for liver fibrosis staging, enabling patients to find and contact MRE-capable locations near them.
  • Clinical Trial Services Core lab services for clinical trials including central image reads, secure data management, quantitative reporting, site training and identification, regulatory support, study start-up/close-out support, quality control, and proprietary in-house analytics for MRE and PDFF biomarkers.

Quantifiable outcome

  • MRE diagnostic performance above 0.90 AUC for classifying all stages of liver fibrosis
  • +5 more outcomes

Companies that use Resoundant

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Resoundant technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature8 records

Resoundant partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • Contract Research Organizations (CROs)coreChannel Partner/ Reseller/ Distributor · 12 August 2020Resoundant leverages connections with talented contract research organizations across the globe for clinical trial services, providing core lab and central image read services for NAFLD/NASH trials.
  • LITMUS Consortium (Pfizer, AstraZeneca, Bristol-Myers Squibb, Allergan, Echosens, HistoIndex)flagshipStrategic or Co-development Partner · 21 May 2019Resoundant joined the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) project - a €46.5m European research initiative funded by the European Innovative Medicines Initiative. The consortium includes 53+ academic centers and pharmaceutical companies working to develop non-invasive diagnostic tests for NAFLD. Resoundant provides advanced 3D MRE software and technological expertise. Budget supported by EU and contributing industry partners including Pfizer (lead EFPIA partner), AstraZeneca, Bristol-Myers Squibb, Allergan, Echosens, and HistoIndex.
  • Siemens HealthineerscoreTechnology or Integration · 1 January 2016Resoundant partnered with Siemens to introduce MRE for their MRI systems, expanding global availability of the technology alongside GE and Philips implementations.
  • Philips HealthcarecoreTechnology or Integration · 1 January 2016Resoundant partnered with Philips Healthcare to implement MRE for their MRI systems. Philips has collaborated with Resoundant on MRE research, including work with Dr. Daniel Podberesky on pediatric MRE applications.
  • GE HealthcarecoreTechnology or Integration · 1 January 2009GE Healthcare was the first MRI manufacturer to implement MRE as an FDA-cleared technology in 2009, making MRE available worldwide. Resoundant worked with GE to commercialize the technology as MR-Touch. GE continues as a key OEM partner implementing standardized MRE across their MRI systems.
  • Mayo CliniccoreStrategic or Co-development Partner · 1 January 2007Resoundant is a Mayo Clinic company founded by Mayo Foundation for Medical Education & Research, Mayo Clinic physicians and researchers. MRE was invented at Mayo Clinic and first implemented as a standard diagnostic test there in 2007. Mayo Clinic continues as key research and clinical development partner. Dr. Richard Ehman serves as both Mayo Clinic radiologist and Resoundant CEO.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Resoundant competitors and assessment

Company assessment

Others

  • Hologic: Hologic is a women's-health and diagnostic imaging company with adjacent capability in clinical diagnostics and quantitative imaging biomarkers relevant to liver disease trial services.
  • Canon Medical Systems: Canon Medical Systems is a major MRI manufacturer that competes in the scanner market where Resoundant's OEM partners compete, and could potentially license or develop elastography as an alternative to MRE.
  • Median Technologies: Median Technologies provides imaging biomarkers and AI-based image analysis for oncology and liver clinical trials, offering central read and quantitative imaging services that overlap with Resoundant's clinical trial services franchise.

Broad incumbents

  • Siemens Healthineers: Siemens Healthineers is an OEM licensee of MRE and a broad incumbent in MRI, with overlapping capability to develop proprietary elastography or substitute imaging modalities in the liver diagnostic space.
  • GE Healthcare: GE Healthcare is both Resoundant's first OEM partner (MRE commercialized 2009) and a broader incumbent in MRI and diagnostic imaging that could develop or substitute competing elastography technologies.
  • Philips Healthcare: Philips Healthcare licenses MRE and is a broad incumbent in MRI and diagnostic imaging with the resources to develop or substitute liver elastography capabilities across its installed base.

Direct peers

  • HistoIndex: HistoIndex is a LITMUS consortium partner offering stain-free digital pathology for NASH/NAFLD assessment; it competes with MRE as an alternative non-invasive or minimally invasive biomarker approach in pharma trials and clinical research.
  • Perspectum Diagnostics: Perspectum offers LiverMultiScan, an MRI-based multiparametric liver assessment that competes head-to-head with MRE for non-invasive liver fibrosis and steatosis quantification in clinical and trial settings.
  • Echosens: Echosens manufactures FibroScan, the dominant ultrasound-based transient elastography device for liver fibrosis assessment, directly competing with MRE for first- and second-line liver fibrosis staging across hepatology practices.

Emerging players

  • OWL (One Way Liver): OWL develops blood-based lipidomics biomarkers for NAFLD/NASH diagnosis and is part of the LITMUS consortium; it represents an emerging non-imaging alternative to MRE for fibrosis and steatosis assessment.

Market position

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Resoundant social profiles

Digital presence

Resoundant compliance and trust

Trust signal

Compliance1 record

Resoundant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resoundant leadership team

Management profile

Number of profiles

Profiles4 records

Resoundant funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resoundant M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resoundant

What does Resoundant do?

Resoundant develops, manufactures, and licenses Magnetic Resonance Elastography (MRE) technology for non-invasive liver fibrosis assessment. The company provides MRE driver hardware systems and processing software to MRI manufacturers (GE Healthcare, Siemens, Philips) as FDA-cleared upgrades, and offers core lab clinical trial services directly to pharmaceutical companies for NAFLD/NASH drug development. Its proprietary technology converts MRI data into quantitative, reproducible biomarkers of liver stiffness.

Is Resoundant a public or private company?

Resoundant is a private company. It is classified as corporate owned and is currently operating.

When was Resoundant founded?

Resoundant was founded in 2006. It employs 11 to 50 people.

Where is Resoundant based?

Resoundant is headquartered in Rochester, United States, in the North America region.

How does Resoundant make money?

Three revenue lines are on record. MRE Driver Hardware Systems are the primary driver. The others are technology Licensing to MRI Manufacturers and clinical Trial Services.

Who are Resoundant's main competitors?

Others on record are Hologic, Canon Medical Systems and Median Technologies. Broad incumbents are Siemens Healthineers, GE Healthcare and Philips Healthcare. Direct peers are HistoIndex, Perspectum Diagnostics and Echosens. OWL (One Way Liver) is listed as an emerging player.

Does Resoundant have an API?

No public API is recorded for Resoundant.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales